Evidence map›Paper›PMID 42432217›Full record

ArticleCancer gene therapy2026

PYGO2 is overexpressed in multiple myeloma patients with 1q21 amplification, driving plasma cell proliferation and cell cycle progression.

Nicolas Thomas Iannozzi, Paola Storti, Rosanna Vescovini, Camilla Sitzia, Andrea Poletti, Valentina Franceschi, Giannalisa Todaro, Gabriella Sammarelli, Denise Toscani, Vincenzo Raimondi and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Nicolas Thomas IannozziDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Paola StortiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Rosanna VescoviniDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Camilla SitziaDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Andrea PolettiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.ORCID http://orcid.org/0000-0002-0753-1248
Valentina FranceschiDepartment of Medical-Veterinary Science, University of Parma, Parma, Italy.
Giannalisa TodaroHematology and BMT Unit, "Azienda Ospedaliero-Universitaria di Parma", Parma, Italy.
Gabriella SammarelliHematology and BMT Unit, "Azienda Ospedaliero-Universitaria di Parma", Parma, Italy.
Denise ToscaniDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Vincenzo RaimondiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Mattia DessenaDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Oxana LunguDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Fazel MohammadiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Matteo ScitaHematology and BMT Unit, "Azienda Ospedaliero-Universitaria di Parma", Parma, Italy.
Matia BernardiHematology and BMT Unit, "Azienda Ospedaliero-Universitaria di Parma", Parma, Italy.
Anna Benedetta Dalla PalmaHematology and BMT Unit, "Azienda Ospedaliero-Universitaria di Parma", Parma, Italy.
Stefania RicciDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Bruno LorussoDepartment of Medicine and Surgery, University of Parma, Parma, Italy.ORCID http://orcid.org/0000-0003-1688-7841
Costanza Anna Maria LagrastaDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Federico QuainiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.ORCID http://orcid.org/0000-0003-2377-4810
Luca Agnelli"Istituto Nazionale dei Tumori" Foundation, Milan, Italy.
Gaetano DonofrioDepartment of Medical-Veterinary Science, University of Parma, Parma, Italy.
Nicola GiulianiDepartment of Medicine and Surgery, University of Parma, Parma, Italy. nicola.giuliani@unipr.it.ORCID http://orcid.org/0000-0003-3457-3774

Funding

Ministero della Salute (Ministry of Health, Italy) PE-2016-02361261
6 · The paper itself

Abstract

Chromosome 1q21 copy number alterations (1q21+) are among the most frequent secondary events in multiple myeloma (MM), correlating with poor prognosis and therapy resistance. However, the molecular drivers of this lesion remain poorly defined. Here, we identify PYGO2, a Wnt/β-catenin co-activator located on 1q21, as a critical effector of MM progression. Analysis of primary CD138

Indexed as

Chromosomes, Human, Pair 1Gene AmplificationIntracellular Signaling Peptides and ProteinsMultiple MyelomaPlasma CellsCell CycleCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansIntracellular Signaling Peptides and ProteinsPYGO2 protein, human

Identifiers

PMID42432217
PMCPMC13498461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.